Private Equity – Talk Bio

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

1 month ago talkbio0Tagged calcium glucarate, Capital, Challenge, Changing, Cognitive function: planning, gains, Investments, Long-term, minimization, Private Equity, rates, Taxes

capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes

bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout

3 months ago talkbio0Tagged Anemia, Sickle Cell, Bluebird Bio, Capital Partners, Carlyle, Cerebral Adrenoleukodystrophy, commercial, David Meek, DKK1 gene, execution, FDA-approved therapies, gene therapy, Genetix Biotherapeutics, Investments, Manufacturing, Private Equity, rebranding, Thalassemia

bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

7 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

8 months ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation

10 months ago talkbio0Tagged Acquisition, Capital, Carlyle, DKK1 gene, Family Turdidae (organism), Financial Stress, gene therapy, Industry, Private Equity

Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

10 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment